| Balance Sheet Detail |
5. Balance Sheet Detail Property and equipment consisted of the following, in thousands:
|
|
|
|
|
|
|
|
|
September 30, 2025 |
|
|
December 31, 2024 |
|
Leasehold improvements |
$ |
7,561 |
|
|
$ |
1,743 |
|
Laboratory and computer equipment |
|
1,946 |
|
|
|
2,004 |
|
Furniture and fixtures |
|
1,758 |
|
|
|
1,210 |
|
Property and equipment, gross |
|
11,265 |
|
|
|
4,957 |
|
Less: accumulated depreciation |
|
(3,868 |
) |
|
|
(3,275 |
) |
Property and equipment, net |
$ |
7,397 |
|
|
$ |
1,682 |
|
Accounts payable and accrued expenses consisted of the following, in thousands:
|
|
|
|
|
|
|
|
|
September 30, 2025 |
|
|
December 31, 2024 |
|
Accounts payable |
$ |
4,671 |
|
|
$ |
1,469 |
|
Accrued clinical trial research and development expenses |
|
22,800 |
|
|
|
14,267 |
|
Accrued other research and development expenses |
|
18,448 |
|
|
|
11,938 |
|
Accrued compensation and benefits |
|
14,595 |
|
|
|
17,508 |
|
Other accrued expenses |
|
6,274 |
|
|
|
2,710 |
|
Income taxes payable |
|
— |
|
|
|
2,061 |
|
Total accounts payable and accrued expenses |
$ |
66,788 |
|
|
$ |
49,953 |
|
|